Fibroblast growth factor 23 serum level in type 2 diabetic Italian subjects with peripheral arterial disease and critical limb ischemia

European Review for Medical and Pharmacological Sciences

Volumn 20, Issue 19, 2016, Pages 4048-4054

  Biscetti, F ^a   Straface, G ^b   Pitocco, D ^c   Angelini, F ^a   Tinelli, G ^c   Landolfi, R ^c   Flex, A ^a,c  

^a CATHOLIC UNIVERSITY   (Italy)

^b St M Goretti Hospital   (Italy)

^c FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

CLI; Critical limb ischemia; FGF 23; Fibroblast growth factor 23; OPG; Osteoprotegerin; PAD; Peripheral artery disease; Type 2 diabetes

Indexed keywords

C REACTIVE PROTEIN; FIBROBLAST GROWTH FACTOR 23; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OSTEOPROTEGERIN; TRIACYLGLYCEROL; FIBROBLAST GROWTH FACTOR;

AGED; ARTICLE; CARDIOVASCULAR RISK; COMPARATIVE STUDY; CONTROLLED STUDY; CRITICAL LIMB ISCHEMIA; DIABETIC PATIENT; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HUMAN; ITALIAN (CITIZEN); MAJOR CLINICAL STUDY; MALE; MOLECULAR DYNAMICS; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; BLOOD; COMPLICATION; ISCHEMIA; RISK FACTOR;

AGED; DIABETES MELLITUS, TYPE 2; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; ISCHEMIA; MALE; PERIPHERAL ARTERIAL DISEASE; RISK FACTORS;

EID: 84995376522     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. MALYAR N M, FREISINGER E, MEYBORG M, LÜDERS F, FÜRSTENBERG T, KRÖGER K, Torsello G, REINECKE H. Low rates of revascularization and high in-hospital mortality in patients with ischemic lower limb amputation: Morbidity and mortality of ischemic amputation. Angiology 2016;67:860-869.
2. LIM H, KIM YU, SUN H, LEE J H, REYNOLDS J M, HANABUCHI S, WU H, TENG B B, CHUNG Y. Proatherogenic conditions promote autoimmune t helper 17 cell responses in vivo. Immunity 2014;40:153-165.
3. OZSARLAK-SOZER G, SEVIN G, OZGUR H H, YETIK-ANACAK G, KERRY Z. Diverse effects of taurine on vascular response and inflammation in GSH depletion model in rabbits. Eur Rev Med Pharmacol Sci 2016;20:1360-1372.
4. SHIMADA T, HASEGAWA H, YAMAZAKI Y, MUTO T, HINO R, TAKEUCHI Y, FUJITA T, NAKAHARA K, FUKUMOTO S, YAMASHITA T. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004;19:429-435.
5. WOLF M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int 2012;82:737-747.
6. SILSWAL N, TOUCHBERRY C D, DANIEL D R, MCCARTHY D L, ZHANG S, ANDRESEN J, STUBBS J R, WACKER M J. FGF23 directly impairs endothelium-dependent vasorelaxation by increasing superoxide levels and reducing nitric oxide bioavailability. Am J Physiol Endocrinol Metab 2014;307:E426-E436.
7. JIMBO R, KAWAKAMI-MORI F, MU S, HIROHAMA D, MAJTAN B, SHIMIZU Y, YATOMI Y, FUKUMOTO S, FUJITA T, SHIMOSAWA T. Fibroblast growth factor 23 accelerates phosphate-induced vascular calcification in the absence of Klotho deficiency. Kidney Int 2014;85:1103-1111.
8. GUTIERREZ O M, MANNSTADT M, ISAKOVA T, RAUH-HAIN J A, TAMEZ H, SHAH, A SMITH K, LEE H, THADHANI R, JÜPPNER H, WOLF M. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008;359:584-592.
9. MIRZA M A, LARSSON A, LIND L, LARSSON T E. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis 2009;205:385-90.
10. INCI A, SARI F, OLMAZ R, COBAN M, DOLU S, SARIKAYA M, ELLIDAG H Y. Soluble Klotho levels in diabetic nephropathy: relationship with arterial stiffness. Eur Rev Med Pharmacol Sci 2016;20:3230-3237.
11. CANZIANI M E, TOMIYAMA C, HIGA A, DRAIBE S A, CARVALHO A B. Fibroblast growth factor 23 in chronic kidney disease: bridging the gap between bone mineral metabolism and left ventricular hypertrophy. Blood Purif 2011;31:26-32.
12. DALAL M, SUN K, CAPPOLA A R, FERRUCCI L, CRASTO C, FRIED L P, SEMBRA R D. Relationship of serum fibroblast growth factor 23 with cardiovascular disease in older community-dwelling women. Eur J Endocrinol 2011;165:797-803.
13. BISCETTI F, STRAFACE G, PORRECA C F, BERTOLETTI G, VINCENZONI C, SNIDER F, STIGLIANO E, ARENA V, ANGELINI F, PECORINI G, BIANCHI A, LANDOLFI R, FLEX A. Increased FGF23 serum level is associated with unstable carotid plaque in type 2 diabetic subjects with internal carotid stenosis. Cardiovasc Diabetol 2015;14:139.
14. RUTHERFORD R B, FLANIGAN D P, GUPTA S K, and THE AD HOC COMMITTEE ON REPORTING STANDARDS SVS/ISCVS. Suggested standards for reports dealing with lower extremity ischaemia. J Vasc Surg 1986;4:80-94.
15. NORGREN L, HIATT W R, DORMANDY J A, NEHLER M R, HARRIS K A, FOWKES F G, TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007:45:S5-67.
16. FRINK R J, ACHOR R W, BROWN A L JR, KINCAID O W, BRANDENBURG R O. Significance of calcification of the coronary arteries. Am J Cardiol 1970;26:241-247.
17. GUTIERREZ O M, JANUZZI JL, ISAKOVA T, LALIBERTE K, SMITH K, CALLERONE G, SARWAR A, HOFFMANN U, COGLIANESE E, CHRISTENSON R, WANG T J, DE FILIPPI C, WOLF M. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009;119:2545-2552.
18. LIM K, LU T S, MOLOSTVOV G, LEE C, LAM F T, ZEHNDER D, HSIAO L L. Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23. Circulation 2012;125:2243-2255.
19. XIAO Y, PENG C, HUANG W, ZHANG J, XIA M, ZHANG Y, LING W. Circulating fibroblast growth factor 23 is associated with angiographic severity and extent of coronary artery disease. PLoS One 2013;8:e72545.
20. PARKER B D, SCHURGERS L J, BRANDENBURG V M, CHRISTENSON R H, VERMEER C, KETTELER M, SHLIPAK M G, WHOOLEY M A, IX J H. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med 2010;152:640-648.
21. IX J H, KATZ R, KESTENBAUM B R, DE BOER I H, CHONCHOL M, MUKAMAL K J, RIFKIN D, SISCOVICK D S, SARNAK M J, SHLIPAK M G. Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). J Am Coll Cardiol 2012;60:200-2007.
22. ARNLOV J, CARLSSON A C, SUNDSTROM J, INGELSSON E, LARSSON A, LIND L, LARSSON T E. Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community. Kidney Int 2013;83:s160-166.
23. O'SULLIVAN E P, ASHLEY D T, DAVENPORT C, KELLY J, DEVLIN N, CROWLEY R, LEAHY A L, KELLY C J, AGHA A, THOMPSON C J, O'GORMAN D J, FITZGERALD P, SMITH D. Osteoprotegerin is higher in peripheral arterial disease regardless of glycaemic status. Thromb Res 2010;126:e423-427.
24. NIU Y, ZHANG W, YANG Z, LI X, WEN J, WANG S, ZHANG H, WANG X, ZHOU H, FANG W, QIN L, SU Q. Association of plasma osteoprotegerin levels with the severity of lower extremity arterial disease in patients with type 2 diabetes. BMC Cardiovasc Disord 2015;15:86.
25. UELAND T, YNDESTAD A, ØIE E, FLORHOLMEN G, HALVORSEN B, FRØLAND S S, SIMONSEN S, CHRISTENSEN G, GULLESTAD L, AUKRUST P. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation 2005;111:2461-2468.
26. GOLLEDGE J, MCCANN M, MANGAN S, LAM A, KARAN M. Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke 2004;35:1636-1641.
27. SANDBERG W J, YNDESTAD A, ØIE E, SMITH C, UELAND T, OVCHINNIKOVA O, ROBERTSON A K, MÜLLER F, SEMB AG, SCHOLZ H, ANDREASSEN A K, GULLESTAD L, DAMÅS J K, FRØLAND S S, HANSSON G K, HALVORSEN B, AUKRUST P. Enhanced T cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. Arterioscler Thromb Vasc Biol 2006;26:857-863.
28. KADOGLOU N P, GERASIMIDIS T, GOLEMATI S, KAPELOUZOU A, KARAYANNACOS P E, LIAPIS C D. The relationship between serum levels of vascular calcification inhibitors and carotid plaque vulnerability. J Vasc Surg 2008;47:55-62.
29. WITTRANT Y, COUILLAUD S, THEOLEYRE S, DUNSTAN C, HEYMANN D, REDINI F. Osteoprotegerin differentially regulates protease expression in osteoclast cultures. Biochem Biophys Res Commun 2002;293:38-44.
30. LIANG K, DONG S R, PENG H. Serum levels and clinical significance of IFN-γ and IL-10 in patients with coronary heart disease. Eur Rev Med Pharmacol Sci 2016;20:1339-1343.
31. LIU Q, JIANG C Y, CHEN B X, ZHAO W, MENG D. The association between high-sensitivity C-reactive protein concentration and diabetic nephropathy: a meta-analysis. Eur Rev Med Pharmacol Sci 2015;19:4558-4568.